Teva And Cipla Will Have ANDAs Withdrawn
After Ignoring Letters From US FDA Over Cetero Bioequivalence Data
Executive Summary
Watson (now Teva) and InvaGen (now Cipla) failed to submit new bioequivalence data following enforcement action against Cetero Research.